Showing 1831-1840 of 4064 results for "".
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
https://reachmd.com/clinical-practice/cardiology/poly-hf-trial-a-polypill-strategy-for-heart-failure-with-reduced-ejection-fraction-hfref/48691/Review the POLY-HF trial results evaluating a once-daily polypill strategy to improve guideline-directed therapy and cardiac function in HFrEF.Managing Pigment for Generation X
https://reachmd.com/topics/energy-based-devices/managing-pigment-for-generation-x/49009/The best products and protocolsBeyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
https://reachmd.com/programs/cme/beyond-the-horizon-in-multiple-myeloma-harnessing-novel-celmod-mechanisms-for-increased-antimyeloma-activity/35916/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivitySustaining Vision: Empowering Optometry for Tomorrow’s Retinal Care
https://reachmd.com/cme/ophthalmology/Sustaining-Vision-Empowering-Optometry-for-Tomorrows-Retinal-Care/32392/Join Drs. Khanani, Sheth, and Vajzovic, to learn how to educate patients about alternative treatment options for retinal diseases.New Contact Lens Technology for Patients With Presbyopia, Dry Eye Disease, and Ocular Surface Disease
https://reachmd.com/programs/empower/new-contact-lens-technology-for-patients-with-presbyopia-dry-eye-disease-and-ocular-surface-disease/56897/A practical guide for new contact lens patients.Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
https://reachmd.com/programs/neurofrontiers/ms-multimodal-aging-signatures-proteomic-biomarkers/54241/Multimodal aging signatures are reshaping our understanding of progression and prognosis in multiple sclerosis (MS). Host Ryan Quigley sits down with Dr. Adil Harroud and Mr. Dylan Hamitouche to learn more about implications for the future of risk stratification and personalized treatment in MS,How Generation X Is Shaping Aesthetic Practice Strategies of the Future
https://reachmd.com/programs/modern-aesthetics/how-generation-x-is-shaping-aesthetic-practice-strategies-of-the-future/49008/The Future of Oral SERDs: Combination Strategies
https://reachmd.com/programs/cme/the-future-of-oral-serds-combination-strategies/39801/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Spotlight on Europe: Adapting the Evidence
https://reachmd.com/programs/cme/spotlight-on-europe-adapting-the-evidence/39808/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Real-World Impact of Evolocumab on MACE Reduction in ASCVD
https://reachmd.com/clinical-practice/cardiology/real-world-impact-of-evolocumab-on-mace-reduction-in-ascvd/39991/Review real-world data on evolocumab and its association with reduced MACE in patients with established atherosclerotic cardiovascular disease.